Clinical Trials
6 trialsNCT05209295 2026-01-12
A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies
Bristol-Myers Squibb
Phase 1 Terminated
NCT04778410 2025-03-20
Study of Magrolimab Combinations in Participants With Myeloid Malignancies
Gilead Sciences
Phase 2 Terminated
NCT04722601 2024-05-16
A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma
University of Chicago
Phase 1/2 Terminated
NCT02900560 2022-06-10
Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer
Translational Research in Oncology
Phase 2 Terminated
NCT02374099 2018-12-14
Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant
Celgene
Phase 2 Terminated
NCT01908387 2015-07-28
Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms
Celgene
Phase 1 Terminated